H. Surmeli

Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma

M. Gumus, U. Kefeli, D. Aydın, 2017, Clinical colorectal cancer.

Approach to mushroom intoxication and treatment: can we decrease mortality?

R. Dabak, C. Dolapçıoğlu, Z. Bahçebaşı, 2012, Clinics and research in hepatology and gastroenterology.

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

A. Bilici, U. Kefeli, D. Aydın, 2015, Clinical and Translational Oncology.

Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

M. Gumus, D. Aydın, T. Korkmaz, 2016, Tumor Biology.

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

M. Gumus, D. Aydın, M. Aliustaoğlu, 2016, Clinical and Translational Oncology.

Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

S. Yıldırım, H. Odabaş, O. Alan, 2023, World Journal of Urology.

The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer

A. Demir, O. Alan, H. Surmeli, 2020, Eurasian Journal of Medical Investigation.

The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

H. Odabaş, N. Turan, H. Surmeli, 2024, Scientific reports.

A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

E. Çavdar, H. Odabaş, N. Turan, 2024, Cancers.